Edition:
India

OPKO Health Inc (OPK.N)

OPK.N on New York Stock Exchange

10.44USD
1:33am IST
Change (% chg)

$0.39 (+3.88%)
Prev Close
$10.05
Open
$10.15
Day's High
$10.47
Day's Low
$10.11
Volume
633,145
Avg. Vol
815,767
52-wk High
$19.19
52-wk Low
$7.13

OPK.N

Chart for OPK.N

About

OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $5,501.82
Shares Outstanding(Mil.): 547.44
Dividend: --
Yield (%): --

Financials

  OPK.N Industry Sector
P/E (TTM): 72.11 34.43 35.43
EPS (TTM): 0.14 -- --
ROI: 4.26 13.73 13.09
ROE: 5.33 14.71 14.22

BRIEF-Opko Health reports Q1 loss per share $0.02

* Q1 earnings per share view $-0.03, revenue view $266.3 million -- Thomson Reuters I/B/E/S

10 May 2016

BRIEF-Opko Health unit and Vifor Fresenius Medical Care enter into development and license deal

* Co's unit and Vifor Fresenius Medical Care Pharma entered into development and license deal for development and marketing of Rayaldee

09 May 2016

BRIEF-OPKO Health presents additional data on rayaldee

* Data showed that mean plasma levels of iPTH and other markers of elevated bone metabolism gradually fell with rayaldee treatment Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

01 Apr 2016

BRIEF-Opko health provides additional data on kidney drug

* Presents additional data on rayaldee to treat secondary hyperparathyroidism in chronic kidney disease

31 Mar 2016

BRIEF-OPKO receives complete response letter from FDA for Rayaldee new drug application

* Opko Health Inc - Opko receives complete response letter from fda for rayaldee new drug application

30 Mar 2016

Competitors

Earnings vs. Estimates